Clinical applications of vascular gene therapy

被引：21

作者：

Rutanen J. ^{[1
]}

Rissanen T.T. ^{[1
]}

Kivelä A. ^{[1
]}

Vajanto I. ^{[1
]}

Ylä-Herttuala S. ^{[1
]}

机构：

[1] A.I. Virtanen Institute, University of Kuopio and Kuopio University Hospital, Kuopio FIN-70211

来源：

Current Cardiology Reports | 2001年 / 3卷 / 1期

关键词：

Vascular Endothelial Growth Factor; Gene Therapy; Gene Transfer; Gene Delivery; Critical Limb Ischemia;

D O I：

10.1007/s11886-001-0007-z

中图分类号：

学科分类号：

摘要：

Despite significant advances in prevention, coronary artery disease remains the leading cause of death in the Western world. Surgical bypass and angioplasty are the primary interventional therapies but they are limited by the problems of restenosis and graft occlusions. Natural response to vascular occlusion involves the formation of collateral vessels that bypass obstructions, but they are often inefficient in relieving ischemia. Vascular gene transfer offers a promising new approach to solve these problems. Its potential has been shown in animal models and in first human trials using vascular endothelial growth factor, fibroblast growth factor, and E2F cell-cycle transcription factor decoy. However, further basic research on gene transfer vectors, gene delivery techniques, and identification of effective treatment genes is needed to improve the efficacy and safety of human vascular gene therapy. Copyright © 2001 by Current Science Inc.

引用

页码：29 / 36

页数：7

共 56 条

[1]

Yla-Herttuala S., Martin J.F., Cardiovascular gene therapy, Lancet, 355, pp. 213-222, (2000)

[2]

Laitinen M., Makinen K., Manninen H., Et al., Adenovirusmediated gene transfer to lower limb artery of patients with chronic critical leg ischemia, Hum Gene Ther, 9, pp. 1481-1486, (1998)

[3]

Baumgartner I., Pieczek A., Manor O., Et al., Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia, Circulation, 97, pp. 1114-1123, (1998)

[4]

Rosengart T.K., Lee L.Y., Patel S.R., Et al., Angiogenesis gene therapy: Phase i assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease, Circulation, 100, pp. 468-474, (1999)

[5]

Losordo D.W., Vale P.R., Symes J.F., Et al., Gene therapy for myocardial angiogenesis - Initial clinical results with direct myocardial injection of phVEGF(165) as sole therapy for myocardial ischemia, Circulation, 98, pp. 2800-2804, (1998)

[6]

Symes J.F., Losordo D.W., Vale P.R., Et al., Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease, Ann Thorac Surg, 68, pp. 830-836, (1999)

[7]

Laitinen M., Hartikainen J., Hiltunen M.O., Et al., Cathetermediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty, Hum Gene Ther, 11, pp. 263-270, (2000)

[8]

Hiltunen M.O., Turunen M.P., Turunen A.M., Et al., Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta, Circulation, 102, pp. 2262-2268, (2000)

[9]

Cavazzana-Calvo M., Hacein-Bey S., De Saint B., Et al., Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease, Science, 288, pp. 669-672, (2000)

[10]

Khuri F.R., Nemunaitis J., Ganly I., Et al., A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer, Nat Med, 6, pp. 879-885, (2000)

← 1 2 3 4 5 6 →